title: Expression of interferon-alpha (IFN-alpha) receptor 2c at diagnosis is associated with cytogenetic response in IFN-alpha-treated chronic myeloid leukemia.
abstract: For the management of chronic myeloid leukemia (CML), prediction or early determination of the response to interferon-alpha (IFN-alpha) treatment is important for identifying nonresponder patients to whom alternative therapy may be proposed. In this study, the levels of expression of both BCR-ABL and subunit 2c of IFN-alpha receptor (IFN-alphaR2c) genes were analyzed at diagnosis in 74 patients with chronic phase CML treated with an IFN-alpha monotherapy. By using blood samples, real-time quantitative polymerase chain reaction was performed to quantify BCR-ABL, IFN-alphaR2c, and G6PDH mRNA as external control. The results were compared with hematologic and cytogenetic responses to IFN-alpha. A wide variation in the BCR-ABL/G6PDH ratio was observed at diagnosis (median, 6.68%; range, 0.18%-41.31%), but no significant association with response to IFN-alpha was observed. In contrast, the variation of IFN-alphaR2c/G6PDH ratio at diagnosis was significantly associated with the achievement of major cytogenetic response (MCR; 34% or lower Ph(+) metaphases). Median values of IFN-alphaR2c/G6PDH ratio for patients achieving MCR and for those who did not achieve it were 110.75% (range, 9.47%-612.30%) and 64.42% (range, 5.96%-425.40%), respectively (P =.037). In addition, this novel molecular factor, combined with the achievement of complete hematologic response at 3 months, makes it possible to predict MCR achievement with high probability by Kaplan-Meier analysis (91% +/- 17% at 24 months; P =.0001). (Blood. 2001;97:3568-3573)
authors.affiliation: Laboratoire Universitaire d'Hématologie, Université Victor Segalen Bordeaux, 146, Rue Léo Saignat, 33076 Bordeaux cedex, France.
authors.forename: C
authors.initials: C
authors.lastname: Barthe
authors.forename: F X
authors.initials: FX
authors.lastname: Mahon
authors.forename: M J
authors.initials: MJ
authors.lastname: Gharbi
authors.forename: C
authors.initials: C
authors.lastname: Fabères
authors.forename: C
authors.initials: C
authors.lastname: Bilhou-Nabéra
authors.forename: A
authors.initials: A
authors.lastname: Hochhaus
authors.forename: J
authors.initials: J
authors.lastname: Reiffers
authors.forename: G
authors.initials: G
authors.lastname: Marit
mesh_terms: D000328:Adult; D000368:Aged; D020732:Cytogenetic Analysis; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000235:genetics; D015870:Gene Expression; D005954:Glucosephosphate Dehydrogenase / Q000235:genetics; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D016133:Polymerase Chain Reaction; D012333:RNA, Messenger / Q000032:analysis / Q000097:blood; D017471:Receptors, Interferon / Q000235:genetics*; D012680:Sensitivity and Specificity; D014407:Tumor Cells, Cultured
chemical_list: D016898:Interferon-alpha; D012333:RNA, Messenger; D017471:Receptors, Interferon; D005954:Glucosephosphate Dehydrogenase; D016044:Fusion Proteins, bcr-abl